Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIaOpen-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Next Previous
Trial Profile

A Phase I/IIaOpen-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YOLT 201 (Primary)
  • Indications Transthyretin-related hereditary amyloidosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ATTR-CM

Most Recent Events

  • 02 Sep 2024 Results(n=226) assessing the use of tafamidis in our center, that features a dedicated Cardiomyopathy Clinic , presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
  • 11 Jul 2024 According to a YolTech Therapeutics media release, the first patient has been dosed in this trial. The first enrolled patient received their first dose on June 28, 2024. Two weeks post-dosing, the patient was in good health with no significant drug-related adverse events observed.
  • 11 Jul 2024 Status changed from planning to recruiting, according to a YolTech Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top